Non-FDG PET/CT in Diagnostic Oncology: a pictorial review
- 228 Downloads
Positron emission tomography/computed tomography (PET/CT) is currently one of the main imaging modalities for cancer patients worldwide. Fluorodeoxyglucose (FDG) PET/CT has earned its global recognition in the modern management of cancer patients and is rapidly becoming an important imaging modality for patients with cardiac, neurological, and infectious/inflammatory conditions.
Despite its proven benefits, FDG has limitations in the assessment of several relevant tumours such as prostate cancer. Therefore, there has been a pressing need for the development and clinical application of different PET radiopharmaceuticals that could image these tumours more precisely. Accordingly, several non-FDG PET radiopharmaceuticals have been introduced into the clinical arena for management of cancer. This trend will undoubtedly continue to spread internationally. The use of PET/CT with different PET radiopharmaceuticals specific to tumour type and biological process being assessed is part of the personalised precision medicine approach.
The objective of this publication is to provide a case-based method of understanding normal biodistribution, variants, and pitfalls, including several examples of different imaging appearances for the main oncological indications for each of the new non-FDG PET radiopharmaceuticals. This should facilitate the interpretation and recognition of common variants and pitfalls to ensure that, in clinical practice, the official report is accurate and helpful.
Some of these radiopharmaceuticals are already commercially available in many countries (e.g. 68Ga-DOTATATE and DOTATOC), others are in the process of becoming available (e.g. 68Ga-PSMA), and some are still being researched. However, this list is subject to change as some radiopharmaceuticals are increasingly utilised, while others gradually decrease in use.
KeywordsPET/CT Non-FDG Pictorial
Tetraazacyclododecane-tetraacetic acid NaI3-octreotide
Tetraazacyclododecane-tetraacetic acid (d)-Phe1-Thy3-octreotate
Tetraazacyclododecane-tetraacetic acid (d)-Phe1-Thy3-octreotide
Fluid attenuated inversion recovery
Human epidermal growth factor receptor 2
Maximum intensity projection
Magnetic resonance imaging
Medullary thyroid cancer
Non-small cell lung cancer
Positron emission tomography/computed tomography
Prostate-specific antigen doubling time
Prostate-specific membrane antigen
Single-photon emission computed tomography
Time to relapse
Carbon-11 is a PET radioisotope with a T1/2 of 20.4 min. Due to the abundance of carbon in the chemistry of biomolecules, all C-11 radiopharmaceuticals demonstrate identical behaviour to natural compounds, allowing real tracing of the biological processes.
Fluorine-18 is a PET radioisotope with a T1/2 of 109.7 min. Due to high chemical stability of the C-F bond in organic compounds, and the high water solubility of F-compounds, F-18 tracers usually exhibit suitable stability and biodistribution in humans. The vast clinical application of F-compounds has led to the development of efficient automated production methods of F-18 tracers for clinical use.
Gallium-68 has a T1/2 of 67.7 min, and is usually obtained from a germanium-68 generator. Due to the T1/2 of 271 days of the parent isotope, 68Ge, the generator can be used for in-hospital production of Ga-68.
Names: CH3[11C]O2, 11C-acetate
After injection 11C-acetate is dispersed in many human tissues including the pancreas, bowels, liver, kidneys, and spleen. The tracer is not excreted in urine under normal circumstances. 11C-acetate is typically incorporated into the cellular membrane in proportion to the cellular proliferation rate or alternatively oxidised to carbon dioxide and water. 11C-acetate may also be converted into amino acids (Seltzer et al. 2004; Karanikas and Beheshti 2014).
• Fast of 4 h is suggested
• 4 or 5 MBq\Kg of 11C-acetate iv
• Uptake time 10–20 min
• Acquisition starts from the pelvis
The main clinical application of 11C-acetate is the detection of non 18F-FDG-avid neoplasm, such as differentiated hepatocellular carcinoma and renal cell carcinomas (Hain and Maisey 2003; Ho et al. 2003; Park et al. 2008). Some other applications of 11C-acetate PET are brain tumours (Liu et al. 2006) and lung carcinomas, while in the past the tracer has been used in prostate cancer (Sandblom et al. 2006).
Names: 16α-[18F] Fluoro-17β-estradiol; 16-Fluoroestradiol, 18F-fluoroestradiol
After injection, the tracer is cleared from the blood and metabolised in 20 min. 18F-fluoroestradiol binds to the oestrogen receptors on the tumour cell surface as well as intratumoural receptors in oestrogen receptor-positive tumours (Liao et al. 2016).
Treatment with oestrogen receptor antagonists (e.g. tamoxifen, fulvestrant, faslodex, oestrogens) should be suspended for at least 5 weeks prior to performing the scan. Aromatase inhibitors and luteinizing hormone releasing hormone agonists may be continued
No fasting is required
200 MBq of 18F-fluoroestradiol iv
Level of binding of 18F-FES to the oestrogen receptors remains stable between 20 and 120 min postinjection. For logistical reasons, scanning procedure should start 60 min after injection
18F-fluoroestradiol is a valuable tracer for the studies of the oestrogen receptor status of primary and metastatic breast or ovarian cancers (Venema et al. 2016; van Kruchten et al. 2013a; van Kruchten et al. 2012; van Kruchten et al. 2013b; Peterson et al. 2011; Linden et al. 2011).
Names: O-(2-[18F] Fluoroethyl)-L-tyrosine; 18F-fluoroethyltyrosine
18F-FET is an amino-acid PET tracer. After injection, the tracer is trapped into cancerous cells, though it is not incorporated into proteins (Abe et al. 2006).
• Fasting for at least 4 h is required
• 4–5 MBq\Kg of 18F-FET iv
• Dynamic one bed brain acquisition for 40 min or static one bed brain acquisitions at 10 and 40–50 min. after injection, for 10 min.
Names: 3′-deoxy-3′-[18F]-fluorothymidine; 18F-fluorothymidine
18F-FLT is an analogue of the nucleoside thymidine; however, substitution of the 3′-F atom prevents from further entering the regular biochemical pathway. FLT is transported from the blood into cells by active transport and phosphorylated by thymidine kinase I without incorporation into the DNA. The conjugated FLT is cleared via the kidneys and excreted in the urine. The accumulated activity in the cells is proportional to thymidine kinase 1 activity as well as cellular proliferation (Grierson and Shields 2000; Oh et al. 2004; Shankar 2012; Turcotte et al. 2007; Vesselle et al. 2003).
• No fasting is required
• 2–3 MBq\Kg of 18F-FLT iv
• Uptake time 50–60 min
18F-FLT is a marker for tumour cell proliferation that has been introduced to improve the accuracy of early FDG PET assessment (Kenny et al. 2007).
Names: L-[methyl-11C] Methionine; 11C-Methionine
11C-Methionine, an essential amino acid, enters the cells by various aminoacid transporters and is involved in the synthesis of proteins and lipids, as well as in the regulation and synthesis of DNA and RNA (Davis et al. 1982; Deloar et al. 1998; Harris et al. 2013).
• Fasting for at least 2 h
• 3 MBq/kg of 11C-Methionine iv
• Injection immediately before the start of the emission
11C-Methionine is used in the detection of brain tumours, primarily gliomas. The gliomas present an increased protein metabolism and capture 11C-Methionine through specific carriers, in contrast to normal tissues that show low uptake.
After injection, the tracer rapidly clears from the circulation (< 3 min), with high clearance by liver and kidneys. Increased metabolism will lead to an increased uptake of choline in the cell membranes and tissues.
11C-choline distributes mainly to the pancreas, kidneys, liver, spleen, and colon. Based upon the relatively low urinary excretion of radioactivity, renal distribution is predominantly to the organ itself, rather than via formation of urine.
The urinary excretion of 18F-fluorocholine has been reported to be about 5% of the administered activity in female patients and 2% in male patients within 60 min after injection (Mitterhauser et al. 2005; DeGrado et al. 2001; DeGrado et al. 2002).
• Fasting of 4 h is suggested
• 4 or 5 MBq\Kg of 11C-choline iv/300 MBq 18F-fluorocholine iv
• Uptake time 2–5 min for 11C-choline/30 min for 18F-fluorocholine
• Acquisition starts from the pelvis for 11C-choline/head-thorax for 18F-fluorocholine
The main clinical application of choline is in prostate cancer patients for staging and restaging the disease in case of biochemical recurrence after primary treatment (Kryza et al. 2008; Evangelista et al. 2013).
Names: [68Ga] prostate-specific membrane antigen ligand; 68Ga-PSMA
Prostate specific membrane antigen (PSMA), a tumour-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumour cells. Upon internalisation of the radiotracer, PSMA-expressing tumour cells can be detected during PET imaging (Heidenreich et al. 2014; Afshar-Oromieh et al. 2016; Demirci et al. 2016).
• Fasting of 4 h is suggested
• 2 or 3 MBq\Kg of 68Ga-PSMA iv
• Uptake time 60–100 min
• Acquisition starts from the pelvis
The main clinical application of 68Ga-PSMA is in prostate cancer patients, namely initial diagnosis (Fendler et al. 2017), nodal staging (Schneider et al. 2016), restaging in case of biochemical recurrence (Calais et al. 2018; Maurer et al. 2016), and theranostic in case of 177Lu-PSMA treatment (Mottet et al. 2011; Zamboglou et al. 2016), or alfa emitters such as 225AcPSMA (Maurer et al. 2016).
Names: L-3,4-Dihydroxy-6-[18F] fluorophenylalanine, 18F-DOPA, 18F-Fluoro-L-DOPA
18F-DOPA reflects all stages of DOPA transport, storage, and metabolism. The tracer is metabolised in the striatum, but also in peripheral tissues such as liver, kidneys, and lung (Rahbar et al. 2017).
• Fasting for more than 4 h
• 2–3 MBq/Kg of 18F-DOPA iv
• Uptake time 60 min for extra-cranial tumours. An additional acquisition of 10 min after injection is suggested in medullary thyroid cancer.
• Uptake time 10 min for primary brain tumours.
18F-DOPA is used in the detection of neuroendocrine tumours. It is the PET tracer of choice for recurrence detection in patients with medullary thyroid cancer and may play a role in the management of patients with pheochromocytoma and neuroblastoma. 18F-DOPA PET/CT is also used in recurrent glioma (Kratochwil et al. 2017; Chondrogiannis et al. 2013; Soussan et al. 2012; Amodru et al. 2018).
Names: [11C] 5-hydroxytryptophan; 11C-HTP
11C-HTP is taken up into neuroendocrine tumours cells by L-large amino acid transporter followed by decarboxylation to serotonin. The resulting end-product is then transported into storage vesicles through the vesicular monoamine transporter as well as went through the metabolic pathway of serotonin (Addeo et al. 2018; Piccardo et al. 2012).
• No special diet is required
• 370 MBq of 11C-HTP iv
• Uptake time 1 h
11C-HTP is used in the detection of neuroendocrine tumours. Since the uptake is related to the serotonergic pathway, 11C-HTP is a possible alternative to 68Ga-DOTA-peptide or 18F-DOPA (Neels et al. 2006).
Names: [68Ga] (1,4,7,10-tetraazacyclododecane-N, N′, N″, N‴-tetraacetic acid)-1- (d)-Phe1-Thy3-octreotate (DOTATATE)- (d)-Phe1-Thy3-octreotide (DOTATOC)- NaI3-octreotide (DOTANOC)
Synthetic somatostatin peptides show long biological half-life and stronger and more specific affinity for somatostatin receptors available on the cellular surface of neuroendocrine tumours. DOTATATE, DOTATOC, and DOTANOC have different affinities for receptor subtypes (Kroiss et al. 2013; Bergeret et al. 2019).
• No special diet is required
• 2–3 MBq\Kg of 68Ga-DOTA-Peptide iv
• Uptake time 1 h
In the management of NETs 68Ga-DOTA-conjugated peptide, PET/CT is used to localise primary tumours and detect sites of metastatic disease (staging); follow-up patients with known disease to detect residual, recurrent or progressive disease (restaging); determine somatostatin status; monitor response to therapy; and select patients with metastatic disease for peptide receptor radionuclide therapy (Skoura et al. 2016; Sundin 2018; Singh et al. 2018; Waseem et al. 2019).
Names: 1-(2-Nitro-imidazolyl)-3-[18F] fluoro-2-propanol; 18F-FMISO
Nitro-group are postulated to undergo reduction in hypoxic condition (pO2 ≤ 2–3 mmHg), forming highly reactive oxygen radicals that subsequently bind covalently to macromolecules inside the cells (Visser et al. 2014; Orlefors et al. 2005).
18F-FMISO is relatively hydrophilic and diffuses across cell membranes, showing a passive distribution in normal tissues, resulting in slow clearance kinetics and a high lipophilicity, resulting in substantially high background.
• Fasting for at least 2 h
• 6 MBq\Kg of 18F-FMISO iv
• Uptake time 3–4 h
PET-CT with 18F-FMISO is a non-invasive method for detecting and characterising hypoxia in several tumours. Ischemia in tumours is associated with a poor prognosis, increased invasion rate, metastasis, and resistance to chemo- and radiation therapy (Institute NC 2013; Nehmeh et al. 2008; Gagel et al. 2006; Hirata et al. 2012; Lin et al. 2008; Lopci et al. 2014; Reischl et al. 2007; Wack et al. 2015).
Names: 1-(5-[18F] Fluoro-5-deoxy-α-D-arabinofuranosyl)-2-Nitroimidazole; 18F-FAZA
Biodistribution and metabolism (Fig. 66)
F-18 FAZA is a 2-nitroimidazole compound (reduced in hypoxic cellular media) with a sugar addition moiety showing more water solubility and better pharmacokinetics compared to 18F-FMISO (Zips et al. 2012; Bollineni et al. 2013; Bollineni et al. 2014).
• No special diet is required
• 370 MBq of 18F-FAZA iv
• Uptake time 2 h
Names: [18F]-Sodium fluoride; 18F-NaF
Fluoride ions are deposited in the bone matrix and reflect: bone remodelling and blood flow. The target organ is bone, but approximately 20% is excreted through the kidney in the urine in the first 1-2 h (Bruine de Bruin et al. 2015; Beheshti et al. 2015).
• No special diet is required but good hydration is important
• 50–200 MBq of 18F-NaF iv
• Uptake time 20–60 min
The indications are those of 99mTc-labelled diphosphonate bone scintigraphy. 18F-NaF PET/CT is more sensitive than bone scintigraphy, for most indications. The choice of PET or SPECT depends on the availability of the radiopharmaceuticals, PET/CT devices, and costs (Lofgren et al. n.d.).
The constant growth of PET/CT including the increasing use of novel non-FDG PET/CT radiopharmaceuticals in cancer patients creates a need for training in the proper interpretation of complex imaging studies with compounds that have very different biodistribution, normal variants, and pitfalls. In addition, the use of several of these non-FDG PET radiopharmaceuticals, such as 68Ga-PSMA and 68Ga-DOTA peptides, constitutes an integral part of the evaluation of patients with cancer for theranostics. As this further increases the radiopharmaceuticals’ clinical relevance, there is also the need for accurate interpretation of non-FDG PET/CT studies.
The authors are very grateful to Pr Ora Israel and Dr Sugitha Sureshkumar for their suggestions and careful and meticulous reading of the paper.
Adherence to national and international regulations
All authors contributed equally to the work. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
- Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM et al (2016) Response assessment in neuro-oncology working group and European association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology 18(9):1199–1208PubMedPubMedCentralCrossRefGoogle Scholar
- Bollineni VR, Koole MJ, Pruim J, Brouwer CL, Wiegman EM, Groen HJ et al (2014) Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. Radiother Oncol 113(2):198–203PubMedCrossRefPubMedCentralGoogle Scholar
- Bruine de Bruin L, Bollineni VR, Wachters JE, Schuuring E, van Hemel BM, van der Wal JE et al (2015) Assessment of hypoxic subvolumes in laryngeal cancer with (18)F-fluoroazomycinarabinoside ((18)F-FAZA)-PET/CT scanning and immunohistochemistry. Radiother Oncol 117(1):106–112PubMedCrossRefPubMedCentralGoogle Scholar
- Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63(6):1040–1048PubMedCrossRefPubMedCentralGoogle Scholar
- Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M et al (2006) [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 6:51PubMedPubMedCentralCrossRefGoogle Scholar
- Institute NC. Investigator’s Brochure for [18F] fluoromisonidazole, 1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole, [18F]FMISO. An investigational positron emission tomography (PET) radiopharmaceutical for injection and intended for use as an in vivo diagnostic for imaging hypoxia in tumors. NIH;5th ed, 2013.Google Scholar
- Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34(9):1339–1347PubMedCrossRefPubMedCentralGoogle Scholar
- Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W et al (2017) Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med 58(10):1624–1631PubMedCrossRefPubMedCentralGoogle Scholar
- Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B et al (2013) 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging 40(4):514–523PubMedCrossRefPubMedCentralGoogle Scholar
- Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM et al (2011) Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 17(14):4799–4805PubMedPubMedCentralCrossRefGoogle Scholar
- Löfgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, Oturai P, Jensen KE, Mørk ML, Reichkendler M, Højgaard L, Fischer BM. A Prospective Study Comparing 99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with 18F-Fluoride PET/CT and 18F-Fluoride PET/MRI for Diagnosing Bone Metastases. J Nucl Med. 2017;58(11):1778–85.PubMedCrossRefPubMedCentralGoogle Scholar
- Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G et al (2016) Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node sStaging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195(5):1436–1443PubMedPubMedCentralCrossRefGoogle Scholar
- Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B et al (2005) Whole-body 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90(6):3392–3400PubMedCrossRefPubMedCentralGoogle Scholar
- Schneider B, Zhu H, Ma X, Cheng Z, Iagaru A, Kopka K et al (2016) Preparation and chemical analysis of clinical-grade 68Ga-PSMA-HBED-CC, an emerging tracer for imaging of prostate cancers. J Nucl Med 57(supplement 2):1117Google Scholar
- Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C et al (2016) The impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom. J Nucl Med 57(1):34–40PubMedCrossRefPubMedCentralGoogle Scholar
- Turcotte E, Wiens LW, Grierson JR, Peterson LM, Wener MH, Vesselle H (2007) Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[18F]fluorothymidine (18F-FLT) for human PET imaging: laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses. BMC Nucl Med 7:3PubMedPubMedCentralCrossRefGoogle Scholar
- van Kruchten M, Hospers GA, Glaudemans AW, Hollema H, Arts HJ, Reyners AK (2013b) Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature. Eur J Cancer 49(18):3850–3855PubMedCrossRefPubMedCentralGoogle Scholar
- Venema CM, Apollonio G, Hospers GA, Schroder CP, Dierckx RA, de Vries EF et al (2016) Recommendations and technical aspects of 16alpha-[18F]Fluoro-17beta-estradiol PET to image the estrogen receptor in vivo: the Groningen experience. Clin Nucl Med 41(11):844–851PubMedCrossRefPubMedCentralGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.